CEBPZ and acute myeloid leukemia: Moreover, at the American Society of Hematology (ASH) 2023 annual meeting, the randomized BIG-1 trial demonstrated that IDAC, compared with HDAC, serves as the standard for consolidation in patients with non-core binding factor (CBF) AML [7].